PharmaNet/i3 names VP and general manager, neuroscience

Monday, July 16, 2012 11:05 AM

PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Robert Lasser, M.D., MBA, vice president and general manager, neuroscience, overseeing the management of all clinical projects handled by PharmaNet/i3’s neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, N.J.

Dr. Lasser, board-certified by the American Board of Psychiatry and Neurology, has more than 18 years of experience in medical practice and the pharmaceutical industry. He joins PharmaNet/i3 from Shire Pharmaceuticals, where he served as general manager for VYVANSE New Uses in multiple central nervous system (CNS) indications. Previously he served as Shire’s senior director in clinical development-medical affairs, overseeing clinical, medical and scientific input to the lifecycle for CNS therapeutics.

He also has held positions of increasing seniority at leading pharmaceutical companies where he directed global CNS medical strategy and clinical studies, and before that was in private practice and held several positions in adult and geriatric psychotherapy and psychopharmacology.

 

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs